Coya Therapeutics, Inc. (NASDAQ:COYA) CEO Acquires $36,700.00 in Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) CEO Arun Swaminathan purchased 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, with a total value of $36,700.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,000 shares in the company, valued at $36,700. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Coya Therapeutics Stock Down 5.9 %

COYA stock opened at $6.81 on Friday. Coya Therapeutics, Inc. has a one year low of $4.75 and a one year high of $10.69. The firm has a 50-day moving average of $7.11 and a two-hundred day moving average of $7.01.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15. As a group, equities research analysts predict that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on COYA shares. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, November 7th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after acquiring an additional 750,338 shares during the period. GHP Investment Advisors Inc. purchased a new stake in shares of Coya Therapeutics in the third quarter worth approximately $169,000. Renaissance Technologies LLC acquired a new stake in shares of Coya Therapeutics during the second quarter worth approximately $101,000. Finally, Gilbert & Cook Inc. purchased a new position in Coya Therapeutics during the second quarter valued at approximately $61,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.